Liver cancer has become the sixth most diagnosed cancer and the fourth leading cause of
cancer death worldwide. Hepatocellular carcinoma (HCC) is responsible for up to 75–85 …

Autophagy is a highly conserved catabolic process and participates in a variety of cellular
biological activities. The phosphoinositide 3-kinase (PI3K)/protein kinase B …

Although hepatocellular carcinoma (HCC) is one of the deadliest health burdens worldwide,
few drugs are available for its clinical treatment. However, in recent years, major …

Hepatocellular carcinoma (HCC, also called primary liver cancer) is one of the most fatal
cancers in the world. Due to the insidiousness of the onset of HCC and the lack of effective …

Sorafenib, a multikinase inhibitor with antiproliferative, antiangiogenic, and proapoptotic
properties, constitutes the only effective first-line drug approved for the treatment of …

Background Hepatocellular carcinoma (HCC) is a common primary malignant tumor which
usually progresses to an advanced stage because of late diagnosis. Sorafenib (Sora) is a …

Background Acquired resistance to sorafenib greatly limits its therapeutic efficiency in the
treatment of hepatocellular carcinoma (HCC). Increasing evidence indicates that long …

Numerous and different types of cancers possess the dysregulation of the mevalonate
pathway as a common feature. Statins, traditionally applied in cardiovascular diseases to …

Background Sorafenib is the only approved first line systemic therapy for advanced
hepatocellular carcinoma (HCC) in the last decade. Tumour resistance to sorafenib has …

Background Hepatocellular carcinoma (HCC) often presents with multiple nodules within the
liver, with limited effective interventions. The high genetic heterogeneity of HCC might be the …